MARKER THERAPEUTICS, INC.

MRKR Healthcare Biotechnology

In the quarter to June 2026, revenue grew 2.75%, EPS grew 69.0% and free cash flow fell 97.8%, each against the same quarter a year earlier.

1.04 0.12 +13.04%
Market cap
$15.3M
P/E
0.0×
Fwd P/E
−1.5×
Dividend yield
—
F-score
3/9
Altman Z
−28.68
Beneish M
−2.92
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — 0.00 0.00

+8 more quarters

P/S ratio
— — 4.80 3.18
P/FCF ratio
— — 0.00 0.00
P/Operating CF
— — (12.01) (5.45)
P/B ratio
— — 1.36 0.81
EV/Sales
— — 1.57 (0.49)
EV/EBITDA
— — 0.00 0.14
EV/FCF
— — (0.31) 0.09
Current Ratio
6.03 4.79 8.39 6.50
Net Debt/EBITDA
4.24 3.59 25.30 8.87
Debt/Equity
0.07 0.07 0.00 0.00
Earnings Yield
— — (57.05%) (138.20%)
Free Cash Flow Yield
— — (105.89%) (180.76%)
Free Cash Flow per Share
(0.19) (0.07) (0.12) (0.16)
Book value per Share
0.63 0.71 1.10 1.10
Free Cash Flow
(3.72) (1.40) (1.90) (2.74)
EV/EBIT
— — 0.00 0.14
Other line items

Show all line items

Columns are period end dates